• Slate Medicines’ antibody drug is designed to block PACAP, a protein associated with migraines. • The Phase 1-ready asset was licensed from China-based DartsBio Pharmaceuticals. • The post Headache Startup Slate Medicines Lands $130M to Bring Novel Migraine Drug Into the Clinic appeared first on MedCity News .

Article Summaries:

  • Slate Medicines, a headache‑focused biotech, has secured $130 million to advance a novel migraine therapy into clinical development. The company’s lead asset is an antibody that targets PACAP, a protein implicated in migraine attacks. The drug, already in a Phase 1‑ready state, was licensed from China‑based DartsBio Pharmaceuticals. The funding will support preclinical work and the initiation of human trials, positioning Slate to bring a potentially new class of migraine treatment to patients. The announcement was reported by MedCity News.

Sources: